CEP is a high potential market, the growth of which is directly related to the global GDP, trade and population. The CEP market is an important part of the overall transportation and distribution industry and reflects the global industrial state and the growth therein.

Globally, CEP market is growing at different paces. On one hand, there is the matured market of the US, while on the other; there are markets which are still underdeveloped. The Asian market holds tremendous growth potential. With China being the most promising market in Asia, opening up opportunities for foreign companies and India picking up the pace, the Asian region is set to grab the limelight in the near future. Markets in Asia are flourishing due to the growing trade between India and China.

The worldwide CEP market is dominated by the four large delivery companies FedEx, UPS, DHL and TNT. The main target of all these companies is to strengthen their networks through their international alliances, agreements, strategic acquisitions and by exploring newer markets.

The report discusses the global CEP market and highlights the growth and characteristics of the various regional markets and countries. The report covers the major markets – US, Europe, and Asia. The report also profiles the four major express delivery companies, focusing in-depth on their business strategies. It also highlights the major trends and issues prevalent in the market.

By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.

For more information, please visit :
http://www.aarkstore.com/reports/Global-Courier-Express-Parcel-CEP-Market-2009-Edition-647.html
Or email us at [email protected] or call +919272852585

With pharmaceutical companies increasingly looking for ways to extend the revenue-earning lifetime of their biggest products, drug delivery has become an important focus of the industry. Kalorama’s Drug Delivery Markets: Implantable / Injectable and Needle-Free Delivery Systems provides detail for business planners on the market for implantable / injectable delivery system markets.

Biopharmaceutical products are driving growth of needle-free systems; there will likely be significant increases in revenues in the vaccine arena. This report looks at that trend and reports current and forecasted revenues for the implantable/injectable drug delivery market, segmented into two main categories:

• Needle-free drug delivery

• Other Injectable/Implantable

Unique analysis offers segmentation of this market for:

• Drug Delivery Technology Revenues

• Pharmaceuticals Sold via Delivery Technology

This breakout makes the report relevant to business plans of either device technology companies or pharmaceutical concerns. (This market analysis does not include drug-eluding stents or prefilled or regular syringes. Kalorama considers these separate markets)

The report covers both pharmaceuticals sold through implantable/injectable delivery systems and the technologies themselves including:

• Detailed Profiles of Key Companies in Implantable/Injectable Delivery

• Brief Round-Up of Smaller Players

• Current Market Size and Forecasts to 2013

• Needle-Free Cost Savings, Protein-Coated Microcrystal Technology, Nanotechnology, and Other Trends and Developments

• Revenue Forecasts

• New Products in Development

Kalorama’s trusted information-gathering process provides most accurate study of the implantable/injectable delivery drug market available today. Information and analysis presented in this report is based on extensive interviews with senior management of top companies in the industry. While major research literature and government information is culled, information is corroborated and key market insights originate from interviews with industry leaders.

Companies Profiled in the report include:

• Alkermes, Inc.

• ALZA Corp.

• Antares Pharma, Inc.

• Bioject Medical Technologies, Inc.

• CyDex, Inc.

• MGI Pharma, Inc

• Nektar Therapeutics

• Pacira Pharmaceuticals, Inc.

• pSivida

• SurModics, Inc

• Zogenix Corporation

• AP Pharma

• Baxter BioPharma Solutions

• QLT USA, Inc

• Ypsomed Holding AG

Kalorama has also published Drug Delivery Markets: Oral Delivery, which details markets for oral technology enhancements which have increased drug product sales and extended patent life.

For more information, please visit :
http://www.aarkstore.com/reports/Drug-Delivery-Markets-Implantable-Injectable-and-Needle-Free-Delivery-Systems-28096.html
Or email us at [email protected] or call +919272852585

The term “companion biomarker” means that a particular diagnostic test is specifically linked to a therapeutic drug either in drug development or in the clinic. Biomarkers of disease have long played an important role in diagnostic medicine as evidenced by the intense use of specific clinical laboratory tests in the diagnosis of disease. Biomarkers can be used in five very distinct ways in drug development: 1) companion biomarkers can be correlated with biological events during drug development in order to validate drug targets or to predict drug response; 2) biomarkers can be used as companion diagnostics in drug development to characterize patient populations in order to better understand the extent to which new drugs reach intended therapeutic targets can alter proposed therapeutic pathways and achieve successful clinical outcomes; 3) biomarkers can be used to stratify patient populations for drug response in primary prevention or disease-modification studies, particularly in specific clinical areas such as neuron degeneration and cancer; 4) clinically useful biomarkers are becoming increasingly useful to make proper therapeutic decisions regarding candidate drugs; and 5) clinically useful biomarkers are becoming increasingly required by the FDA and other outside authorities to make proper regulatory decisions regarding candidate drugs. This report describes new biomarker technology platforms developed for the analyses of drug targets that are connected to the effectiveness of therapeutic agents in a clinical setting. The emphasis is on those companies that are actively developing and marketing new companion diagnostic tests for performing biomarker tests during drug development, as opposed to the more routine and clinically accepted companion markers that are manufactured and marketed by large diagnostic companies for routine clinical use.

Table of Contents :   1. Overview 13
1.1 Statement of Report 13
1.2 About This Report 13
1.3 Scope of the Report 13
1.4 Objectives 13
1.5 Methodology 15
1.6 Executive Summary 16

2. Introduction: Companion Diagnostics in Drug Development 19
2.1 Companion Diagnostics as Biomarkers 20
2.1.1 Potential Benefits of Biomarkers as Companion Diagnostics 22
2.2 Biomarkers in Different Phases of Drug Development 22
2.2.1 Drug Discovery and Development Process 22
2.2.2 Biomarkers in Drug Development 24
2.3 Drug Targets 24
2.3.1 Target Discovery Using Functional Genomics 26
2.3.2 Functional Genomics 26
2.3.3 Target Validation 28
2.3.3.1 Target Discovery 28
2.3.3.2 Lead Identification 28
2.3.4 Target and Biomarker Discovery 29
2.3.4.1 Biomarker Validation 29
2.4 Biomarkers in Drug Discovery, Development and Clinical Diagnostics 29
2.4.1 Role of Biomarkers in Drug Discovery, Preclinical, Clinical Development and Diagnostics 29
2.4.2 The Pipeline Problem 31
2.4.3 Biomarkers in the Drug Discovery Process 32
2.4.4 Segmentation of Biomarker Usage 32
2.4.5 Efficacy of Biomarkers as Surrogate Endpoints 33
2.4.6 Biomarkers Used to Reduce the Cost of Drug Development 34
2.4.7 Biomarkers: Challenges and Opportunities 34
2.4.8 Biomarkers in Early Safety and Toxicity Assessment 35
2.4.9 Biomarkers in Determining Validation Parameters 35
2.4.10 Challenges in Development of Biomarkers 36
2.4.11 Using Biomarkers in Early Clinical Development 36
2.4.12 Translational Biomarkers 36
2.4.13 Use of Biomarkers in “Go”/No-Go” Decisions 37
2.4.14 Diagnostic Tests 37
2.4.15 Biomarkers in Deal Making 37
2.4.16 Payors Use Biomarkers in Decision-Making 37
2.5 World Pharmaceutical Markets 38
2.5.1 World Market Summary 38
2.5.2 Company Performance in this Segment 40
2.5.3 Forces Affecting the Structure of the Pharmaceutical Industry 41
2.5.3.1 Threats 41
2.5.3.2 Competitive Forces 42
2.6.1 Industry Overview 42
2.6.1.1 Pharmaceutical Industry Drug Pipeline 44
2.6.1.2 Asia-Pacific to Replace United States and Europe as Pharmaceutical Industry Center 54
2.6.1.3 The Changing Pharmaceutical Business Model 54
2.6.2 Benefits for Companion Diagnostic Tests in Drug Development 55
2.6.3 Strategies for the Creation of Partnerships – Predicting and Overcoming Challenges in Creating Drug Response Profiling Diagnostics 57
2.6.4 Options and Applications 57
2.6.4.1 Clinical Applications of Genomics: The Use of Evidence Based Frameworks by Decision-Makers 57
2.6.5 Challenges, Drivers and Trends 58
2.6.5.1 Macro Trends in Biomarkers 58
2.6.5.2 Biomarkers: Industry SWOT Analysis 61
2.6.6 Breakaway Technologies 62
2.6.7 Collaboration for Companion Diagnostics 63
2.6.8 Key Stake Holders in Companion Diagnostics 63
2.9 Future Developments 65

For more information, please visit :
http://www.aarkstore.com/reports/Companion-Biomarkers-in-Drug-Development-13521.html
Or email us at [email protected] or call +919272852585

The purpose of this TriMark Publications report is to describe the sector trends within the point of care testing (POCT) diagnostic market. It examines those measurement devices and their reagents and supplies that are utilized in hospitals, clinics, commercial laboratories and research institutions to detect cells and proteins for the purpose of diagnosis and monitoring of disease. This study includes all of the generally-accepted clinical analytical activities that are currently in use today. Additionally, an analysis of business and technology trends and developing areas of point of care and HPV testing is provided, along with a review of the market for point of care testing equipment and supplies in the clinical and research market segments, using screening reagents and instruments for analysis of individual components in blood, serum or plasma. This report defines U.S. and global market dollar sales volume and analyzes factors that influence the size and growth of market segments.

Table of Contents : 1. Overview 6
1.1 Statement of Report 6
1.2 Scope of the Report 8
1.3 Objectives 9
1.4 Methodology 9
1.5 Executive Summary 10

2. Overview of Diagnostic Point of Care Testing 12
2.1 Key Issues in the Point of Care Diagnostic Testing Sector 12
2.1.1 Current Market Trends and Drivers 12
2.1.2 Effectiveness of POCT 13
2.1.3 New Growth Areas for POCT 14
2.1.4 Advantages of POCT in a Clinical Setting 14
2.1.5 Pricing and Reimbursement Issues 14
2.1.6 Key Customer Segments 14
2.2 Global Point of Care Marketplace 14
2.3 Shifts from Central Lab Testing to POCT 16
2.4 Geographical Distribution 16
2.5 Emerging New Technologies 17
2.6 Challenges of POCT 18
2.7 Key Issues for POCT 18
2.7.1 Locations of POCT 18
2.7.2 Hospital Lab Rapid Tests 19
2.7.3 Doctor’s Office Laboratory 19
2.7.4 Non-Hospital POCT 19
2.7.5 Home Monitoring 19
2.7.6 Milestones in Technology Development 20
2.7.7 Drive for Decentralization from Lab to Patient 21
2.7.8 Expanded Reimbursement 21
2.7.9 Competitive Landscape for POCT 24
2.8 The Future of POCT 24

For more information, please visit :
http://www.aarkstore.com/reports/Point-of-Care-Diagnostic-Testing-Sector-Trends-1333.html
Or email us at [email protected] or call +919272852585

The purpose of this Publications (http://www.aarkstore.com/reports/Over-the-Counter-Diagnostic-Products-World-Markets-1331.html) analysis is to describe the specific market segments of the over-the-counter (OTC) diagnostic products and home healthcare markets. It examines the diagnostic measurement devices and their reagents and supplies that are utilized in clinics and by patients directly in their homes to diagnose and monitor disease. This study also includes a review of home healthcare kits and devices that measure health-related conditions. Focus is on market dynamics and current market drivers of the OTC and home self-testing diagnostics market. This report also looks at the industry challenges and potential threats, and it makes strategic recommendations for boosting market share. The analysis covers healthcare-related devices that are designed for the home market in order to allow consumers to assess their health status through self-testing. In addition, this review examines some biowarfare detection systems. The emphasis in this report is on those companies and products that are actively developing and marketing diagnostic reagents and supplies in market segments that are targeted for direct sale to the public. It is believed that this market segment has the potential for growth rates above 15% per year over the next five years in some of the less well-explored and well-developed areas.

Table of Contents : 1 Overview 7
1.1 Statement of Report 7
1.2 About This Report 7
1.3 Scope of the Report 9
1.4 Objectives 10
1.5 Methodology 11
1.6 Executive Summary 11

2 Sector Overview 17
2.1 Global Diagnostic Products Industry 17
2.2 Global OTC Diagnostic Products Industry 18
2.2.1 General Global Market 18
2.2.2 German OTC and Home Self-Testing Diagnostic Markets 22
2.2.3 U.K. OTC and Home Self-Test Diagnostic Markets 22
2.2.3.1 U.K. Market Statistics 23
2.2.3.2 U.K. Competitive Analysis 24
2.2.3.3 U.K. Market Access 25
2.2.4 French OTC Diagnostic Market 25
2.2.5 Italian OTC Diagnostic Market 26
2.2.6 Spanish OTC Diagnostic Market 26
2.2.7 Japanese OTC Diagnostic Market 27
2.2.8 Chinese OTC Diagnostic Market 28
2.3 Description of the U.S. OTC Diagnostics Industry Segment 29
2.3.1 Market Overview 29
2.3.2 Diagnostic Test Categories 30
2.4 Market Drivers in the OTC Diagnostics Sector 31
2.4.1 Overview 31
2.4.2 Market Segments 31
2.5 Key Players in the OTC Diagnostics Segment 32
2.6 Sector Analysis 34

3 Market Analysis: Size, Growth, Share and Competitors 35
3.1 Glucose Monitoring 35
3.1.1 Glucose Control in Diabetic Patients 41
3.1.2 Tight Glucose Control in Treating Diabetes 41
3.1.3 Glucose-Monitoring Devices 42
3.1.4 Key Issues for Glucose Monitoring 43
3.1.5 Glucose Device Description 43
3.1.6 Precision in Glucose Meters 44
3.1.7 Limitations of Existing Glucose Monitoring Products 45
3.1.8 Over-the-Counter (OTC) Self-Testing Glucose Market 46
3.1.9 Worldwide Glucose Testing Market 48
3.1.9.1 U.S. Market 49
3.1.9.2 European Market 53
3.1.9.3 Asian Market 54
3.1.9.3.1 Japanese Market 55
3.1.9.3.2 China Market 56
3.1.9.3.3 Indian Market 58
3.1.9.4 ROW Markets 59
3.1.10 Reagents and Equipment 59
3.1.10.1 Blood Glucose Monitoring 59
3.1.10.2 Lancets 60
3.1.10.3 Blood Glucose Monitor and Insulin Doser 67
3.1.10.4 Blood Glucose Reagent Test Strips 67
3.1.10.5 Control Solutions and Calibrators 68
3.1.10.6 Sharps Devices 68
3.1.10.7 Needle Destruction Devices 69
3.1.10.8 Voice-Operated Glucose Meters 70
3.1.11 Glucose Meters 73
3.2 Pregnancy Testing 98
3.2.1 Major Players 99
3.2.1.1 U.S. Market 100
3.2.1.2 European Market 101
3.2.2 Diagnostic Kit Information 101
3.3 Hepatitis Testing 108
3.4 Drugs of Abuse Screening Testing 111
3.5 Infectious Disease Testing 126
3.5.1 HIV 128
3.5.2 Tuberculosis Testing 139
3.5.3 Infectious Disease Testing in Non-medical Settings 140
3.5.4 West Nile Virus 142
3.5.5 Urinary Tract Infections 143
3.6 Cholesterol Testing 144
3.7 Coagulation Testing 146
3.8 Urine Dipstick Testing 153
3.9 Fertility Testing 153
3.9.1 Players 155
3.9.2 Diagnostic Test Kits 156
3.10 At-Home DNA Analysis 159
3.11 Biowarfare Detection 164
3.12 Home Patient Monitoring Devices 166
3.13 Home Patient Alert Systems 167
3.14 Home Genetic Testing Kits 167
3.15 Home Paternity Testing 171
3.16 Health Hazards Detection 172
3.16.1 Lead 172
3.16.2 Radon 172
3.16.3 Asbestos 172
3.16.4 Pesticides 173
3.16.5 Mold 173
3.16.6 Carbon Monoxide 173
3.16.7 Water Quality 173
3.16.8 Bacteria in Water 173
3.17 Thyroid Disease 174
3.18 Carpal Tunnel 174
3.19 Allergies 174
3.20 Nutrition and Wellness 174
3.20.1 Testosterone and Male Hormones 174
3.20.2 Female Hormones 174
3.20.3 Antioxidants 174
3.20.4 Sleep Apnea 175
3.20.5 Mineral Check 175
3.20.6 Stress Check 175
3.21 Colorectal Cancer (Occult Blood) Testing 176
3.22 Alzheimer?s Disease Home Screening Test 177
3.23 Tobacco Testing 177

For more information, please visit :
http://www.aarkstore.com/reports/Over-the-Counter-Diagnostic-Products-World-Markets-1331.html
Or email us at [email protected] or call +919272852585

This Publications report (http://www.aarkstore.com/reports/Disposable-Medical-Supplies-Markets-1507.html) is intended to provide basic marketing data pertaining to the U.S. and worldwide market segments of the disposable medical supplies market, including: surgical gowns, surgical drapes, isolation gowns, surgical and examination gloves, institutional incontinence disposables, operating room (OR) custom kits and trays, non-OR custom packs, shoe covers, masks, disposable coveralls and lab coats, headwear, protective eyewear, sterile wipes, swabs and mops. Each market segment is analyzed to determine size, growth rates, sales projections and factors influencing growth in the U.S. and internationally. Unit and dollar volume are used to indicate market sizes. Growth rates and sales projections are reported in units and U.S. dollars. Market shares are based on units and apply to the U.S. only.

Table of Contents : 1. Introduction 10
1.1 Objectives 10
1.2 Scope 10
1.3 Methodology 11
1.4 Executive Summary 12

2. Disposable Medical Supplies Market 14
2.1 Overview 14
2.2 Technological Advancements in Disposable Medical Supplies 14

3. Nanotechnology in Medical Devices and Disposables 15
3.1 Implants 16
3.2 Tissue Engineering 16
3.3 Sensors 16
3.4 Stents 16
3.5 Nanostructured TiOx Ultra Thin Films 16
3.6 Drug Delivery 17
3.7 Heat Therapy 17
3.8 MRI/X-ray 17
3.9 Bone Cement 17

4. Medical Design Excellence Awards for Medical Disposables 18
4.1 Winning Disposable Medical Products and Suppliers, 2008 18
4.1.1 HemCon® Bandage 18
4.1.2 Veramyst™ (Fluticasone Furoate) Nasal Spray Delivery Device 19
4.1.3 Akreos® AO Microincision Lens, Model MI60 19
4.1.4 GeeWhiz Male External Condom Catheter 19
4.1.5 Natural Nurser™ Baby Bottle 20
4.1.6 NovoFine® Autocover™ Automatic Safety Pen Needle 20
4.1.7 Uresta™ Continence Care Kit 20
4.1.8 InteguSeal™ Microbial Sealant 21
4.1.9 Patient Registration Mask 21
4.2 Winning Disposable Medical Products and Suppliers in 2007 21
4.2.1 Thermoplastic Drill Template Set 21
4.2.2 Ospol Dental Implant System Packaging 22
4.2.3 Episure™ AutoDetect Epidural Syringe 22
4.2.4 Odor Absorbing Hydrocolloid Wound Dressing 23
4.2.5 SureSkin® Central Catheter and I.V. Dressing 23
4.2.6 Gynecare TVT Secur™ System for Treating Stress Urinary Incontinence 23
4.2.7 Conveen® Optima Silicone Urisheath 24
4.3 Winning Disposable Medical Products and Suppliers, 2006 24
4.3.1 eFlow® Electronic Nebulizer 24
4.4 Winning Disposable Medical Products and Suppliers, 2005 24
4.4.1 OptraGate® 24
4.4.2 RelyX™ Luting Plus Cement 25
4.4.3 3M™ Foam Adhesive Dressing 25
4.4.4 ClozeX Wound Closure Device 25

5. Overview of Non-woven Industry 26
5.1 Future of Global Non-woven Production 31
5.2 U.S. Non-woven Market 33
5.3 Non-woven Production in Europe 34
5.3.1 Non-woven Industry in Turkey 34
5.4 Non-woven Industry in Asia 35
5.4.1 India is the Next Booming Market for Non-wovens 36
5.5 Non-wovens in Medical Sector 39
5.6 U.S. Medical Non-woven Market 43
5.7 Characteristics of the Medical Textile Market 45
5.8 Trends in World Trade of Medical Textiles 47

6. Surgical Gowns 49
6.1 Size and Growth Rate of the Market 49
6.2 Company Profiles 52
6.2.1 Kimberly-Clark HealthCare 52
6.2.2 Cardinal Health Corp. 53
6.2.3 Medline Industries, Inc. 53
6.2.4 Mölnlycke HealthCare 53
6.2.5 Johnson & Johnson 54
6.2.6 Dynarex Corporation 54
6.2.7 3M HealthCare 55
6.3 Competition in the Medical Gown Market 55
6.4 Overall Trends 56

For more information, please visit :
http://www.aarkstore.com/reports/Disposable-Medical-Supplies-Markets-1507.html
Or email us at [email protected] or call +919272852585

Clinical immunoanalyzer analysis is one of the most important functions of clinical laboratory analysis. By all accounts, automated immunoassay testing is the most rapidly developing of the traditional clinical laboratory sectors. Clinical immunoanalyzer analysis usually refers to determining the concentration or activity of protein, carbohydrate, lipid, enzyme or small molecule in easily collected body fluids, such as blood, serum, plasma or urine. However, it is not necessarily limited to these purposes. The analysis of virtually any biologically active substance in any place in the body can generally be defined as clinical immunoassay testing. In fact, traditional specialization barriers, such as microbiology, hematology, blood banking, immunology and even anatomical pathology are fading rapidly, both operationally and instrumentally. This (http://www.aarkstore.com/reports/Clinical-Immunoanalyzer-Markets-1188.html) report deals with the traditional scope of clinical immunoassay, while looking at the emerging technology trends in this sector. The purpose of this study is to describe the specific segments of the global clinical immunoanalyzer instrumentation market. Within this area, the highly-active segments in terms of innovation and growth are covered. Specifically, it examines the markets for small labs and highly-automated large lab platforms, as well as the market for accessory equipment, such as reagents and supplies. Emphasis is on those companies and products that are actively developing and marketing immunoanalyzer products for clinical setting, including hospitals, independent labs, physician’s offices and clinics.

Table of Contents :
1. Overview 6
1.1 Objectives 6
1.2 Methodology 6
1.3 TriMark Publications Report Research and Data Acquisition Structure 8
1.4 Scope of the Report 8
1.5 Executive Summary 9

2. IVD Clinical Immunoanalyzer Market 11
2.1 Introduction 11

3. IVD Clinical Immunoanalyzer Market Analysis 13
3.1 Markets 13
3.1.1 Global Markets 13
3.1.2 Global Drivers of Clinical Immunoanalyzer Testing 14
3.1.3 Global Outlook 15
3.1.4 U.S. Market 16
3.1.5 European IVD Market 18
3.1.5.1 German Clinical Immunoanalyzer Diagnostic Markets 21
3.1.5.2 U.K. Clinical Immunoanalyzer Testing Diagnostic Market 23
3.1.5.3 French Clinical Laboratory Diagnostic Testing Market 23
3.1.5.4 Italian Clinical Immunochemistry Diagnostic Market 24
3.1.5.5 Spanish Immunoanalyzer Market 25
3.1.5.6 Finnish Immunoanalyzer Market 25
3.1.5.7 Belgian Immunoanalyzer Market 26
3.1.5.8 Swiss Immunoanalyzer Market 26
3.1.5.9 Dutch Immunoanalyzer Market 26
3.1.5.10 Portuguese Immunoanalyzer Market 27
3.1.5.11 Austrian Immunoanalyzer Market 27
3.1.5.12 Greek Immunoanalyzer Market 28
3.1.5.13 Polish Immunoanalyzer Market 28
3.1.5.14 Romanian Immunoanalyzer Market 29
3.1.6 Indian Clinical Analyzer Diagnostic Market 29
3.1.6.1 India’s in vitro Diagnostic Testing Industry 29
3.1.7 Japanese Clinical Immunoanalyzer Testing Market 34
3.1.8 Country Clinical Analyzer Smaller Markets 34
3.1.8.1 China Clinical Analyzer Market 34
3.1.8.2 Canada Clinical Analyzer Market 38
3.1.8.3 Brazil Clinical Analyzer Market 39
3.1.8.4 Turkey Clinical Immunoanalyzer Market 39
3.1.8.5 Australia Clinical Analyzer Market 40
3.1.8.6 Rest of the World Clinical Analyzer Testing Market 40
3.1.9 Overview of Asian Healthcare Market 40
3.1.9.1 Singapore 41
3.1.9.2 Malaysia 41
3.1.9.3 Thailand 41
3.1.9.4 Indonesia 41
3.1.9.5 Philippines 42
3.1.9.6 South Korea 42
3.1.9.7 India 42
3.1.9.8 Hong Kong 43
3.1.9.9 Taiwan 43
3.2 Clinical Immunoanalyzer Sector 44
3.2.1 Industry-Served Markets 45
3.2.2 Industry Players 45
3.2.2.1 Manufacturing Companies 45
3.2.3 Market Specialization 46
3.2.4 Revenue and Reimbursement 48
3.2.5 Companies 49
3.3 Outlook for Clinical Immunoanalyzer Testing 50
3.3.1 Long-Term Changes 50
3.3.2 Market Drivers 51
3.3.3 The Limits to Growth 51
3.3.4 Hot Sectors in IVD Market 52
3.3.5 Key Technologies 53
3.3.6 Analyzer Integration Chemistry/Immunoassay 53
3.3.7 Conclusion 54

4. Clinical Immunoanalyzer Instrument Market by Sector 55
4.1 Market Analysis: Size, Growth, Share and Competitors 55
4.1.1 Immunochemistry Analyzers 55
4.1.2 Large-Volume Immunochemistry Analyzers 55
4.1.2.1 Abbott Diagnostics 55
4.1.2.2 Siemens Medical Solutions Diagnostics 56
4.1.2.3 Beckman Coulter, Inc. 59
4.1.2.4 Dade Behring (Acquired by Siemens) 60
4.1.2.5 Diagnostics Products Corporation (Acquired by Siemens Healthcare Diagnostics) 61
4.1.2.6 Olympus America, Inc. 62
4.1.2.7 Ortho-Clinical Diagnostics 63
4.1.2.8 Roche Diagnostics Corp. 65
4.1.2.9 Tosoh Bioscience 67
4.1.3 Batch-Type Immunoassay Analyzers 69
4.1.3.1 Bio-Rad 69
4.1.3.2 Dade Behring (Acquired by Siemens) 69
4.1.3.3 Diamedix 69
4.1.3.4 Tosoh 72
4.1.4 Small-Volume to Mid-Volume Immunoassay Analyzers 72
4.1.4.1 Awareness Technology, Inc. 72
4.1.4.2 Siemens Healthcare Diagnostics, Inc. 72
4.1.4.3 Beckman Coulter, Inc. 73
4.1.4.4 bioMérieux SA 74
4.1.4.5 Dade Behring (Acquired by Siemens) 74
4.1.4.6 Randox Laboratories Ltd. 78
4.1.4.7 Tosoh Corporation 79
4.1.5 Other Immunoassay Analyzers 80
4.1.5.1 Inverness Medical Professional Diagnostics 80
4.1.5.2 Hycor BioMedical (A Part of Agilent Technologies) 80
4.1.5.3 Phadia AB 80
4.1.5.4 Trinity Biotech PLC. 81
4.1.5.5 Diasorin 81
4.1.5.6 Grifols U.S.A. Inc. 81
4.1.5.7 Bio-Rad Laboratories, Inc. 82
4.1.5.8 SFRI Diagnostics 82
4.1.5.9 Qualigen Inc. 82
4.1.5.10 PerkinElmer Inc. 82
4.1.5.11 Innotrac Diagnostics Oy 83
4.1.5.12 Tecan Group Ltd. 83

For more information, please visit :
http://www.aarkstore.com/reports/Clinical-Immunoanalyzer-Markets-1188.html
Or email us at [email protected] or call +919272852585

Clinical hematology analyzer analysis is one of the oldest and most important sectors of clinical laboratory analysis. The hematology instrument and reagent market is centered around a group of instruments called hematology analyzers. The term clinical hematology analyzer usually refers to an automated instrument for determining the presence, number and type of cellular elements in easily collected body fluids, such as blood. However, it is not necessarily limited to these determinations. The hematology analysis always includes determination of non-cellular parameters in blood, such as hemoglobin and hematocrit. Other closely related areas of clinical interest are coagulation and flow cytometry. In fact, traditional specialization barriers, such as microbiology, hematology, blood banking, immunology and even anatomical pathology are rapidly fading both operationally and instrumentally. But for the sake of defining the subject to a reasonable size, the more traditional scope of clinical hematology analyzer will be the focus of this examination. The purpose of this Publications report is to describe the specific segments of the global clinical hematology analyzer instrumentation and reagent marketplace. The review covers those segments that are highly active in terms of innovation and growth. Specifically, this study examines the markets for small-lab, as well as highly-automated large-lab, platforms and accessory equipment, such as reagents, supplies and add-on equipment from original equipment manufacturers.

Table of Contents : 1. Overview 7
1.1 Objectives of the Report 7
1.2 Methodology 8
1.3 Scope of the Report 8
1.4 Executive Summary 9

2 IVD Clinical Hematology Analyzer Market 11
2.1 Introduction 11
2.2 Key Product Segments 17
2.2.1 Hematology and Associates Instruments 17
2.2.1.1 Hematology Analyzers 17
2.2.1.2 Hematology Instruments Offerings by Major Players 17
2.2.1.2.1 Hematology Reagents and Controls 18
2.2.1.2.2 Hematology Point of Care Instruments 19
2.2.1.3 Flow Cytometers 20
2.2.1.3.1 Flow Cytometry Technology Platforms 20
2.2.1.3.2 Clinical Applications of Flow Cytometry 20
2.2.1.3.2.1 Leukocyte Analysis 20
2.2.1.3.2.2 Immunophenotyping of Leukemias and Lymphomas 21
2.2.1.3.2.3 Neutropenia 21
2.2.1.3.2.4 Platelet Analysis 21
2.2.1.3.2.5 T Cell Subsets 22
2.2.1.3.2.6 Reticulocyte Count 22
2.2.1.3.3 Flow Cytometry Market Growth 22
2.2.1.3.3.1 Applications 23
2.2.1.3.3.2 Market Size 23
2.2.1.3.3.3 Instrumentation Preferences 24
2.2.1.3.3.4 Reagent Selection and Use 24
2.2.1.3.3.5 Instrument Manufacturers 25
2.2.1.3.3.6 Future Directions of Flow Cytometry 26
2.2.1.4 Coagulation Analyzers 26
2.2.1.4.1 Coagulation Market Size 27
2.2.1.4.2 Prothrombin Time Test 28
2.2.1.4.3 Activated Partial Thromboplastin Time (APTT) 28
2.2.1.4.4 Clinical Advantages of Coagulation Testing 29
2.2.1.4.5 Coagulation Instruments 30
2.2.1.4.5.1 Roche Diagnostics 30
2.2.1.4.5.2 Avocet Medical 31
2.2.1.4.5.3 International Technidyne Corporation 31
2.2.1.4.5.4 Cardiovascular Diagnostics 32
2.2.1.4.5.5 Diagnostica Stago’s STA-R Evolution 32
2.2.1.4.5.6 Other Companies 33
2.2.1.4.5.7 Coagulation Reagents 34
2.2.1.5 Hemoglobinometers 34
2.2.1.6 Slide Stainers 34
2.2.1.7 Differential Counters 36
2.2.1.8 Hematology Stains 37
2.3 Blood Components 37
2.3.1 Complete Blood Count (CBC) 37
2.3.2 Red Blood Cells (RBCs) 38
2.3.3 White Blood Cells (WBCs) 38
2.3.4 Platelets 39
2.3.5 Hematocrit (HCT) 39
2.4 Hematology Tests 39
2.5 The Coulter Principle 40
2.6 Blood Collection 40

3. IVD Clinical Hematology Analyzer Market 41
3.1 Markets 41
3.1.1 Global Markets 41
3.1.2 Global Drivers of Clinical Hematology Analyzer Testing 45
3.1.3 Global Outlook 45
3.1.4 U.S. Market 46
3.1.5 European Market 48
3.1.5.1 German Clinical Hematology Analyzer and Reagent Diagnostic Markets 51
3.1.5.2 U.K. Clinical Hematology Market 53
3.1.5.3 French Clinical Hematology Market 55
3.1.5.4 Italian Clinical Hematology Market 55
3.1.5.5 Spanish Clinical Hematology Market 56
3.1.5.6 Belgian Clinical Hematology Market 56
3.1.5.7 Swiss Clinical Hematology Market 56
3.1.5.8 Dutch Clinical Hematology Market 57
3.1.5.9 Portuguese Clinical Hematology Market 57
3.1.5.10 Austrian Clinical Hematology Market 58
3.1.5.11 Greek Clinical Hematology Market 58
3.1.5.12 Polish Clinical Hematology Market 59
3.1.5.13 Czech Clinical Hematology Market 59
3.1.5.14 Finnish Clinical Hematology Market 60
3.1.5.15 Scandinavian Clinical Hematology Market 60
3.1.6 Asian Market 61
3.1.6.1 Indian Clinical Hematology Market 61
3.1.6.1.1 India’s in vitro Diagnostic Testing Industry 61
3.1.6.1.2 Major Indian IVD Companies 62
3.1.6.2 Japanese Clinical Hematology Market 64
3.1.6.3 Chinese Clinical Hematology Market 64
3.1.7 Country Clinical Hematology Smaller Markets 68
3.1.7.1 Canada Clinical Hematology Market 68
3.1.7.2 Brazil Clinical Hematology Market 68
3.1.7.3 Turkey Clinical Hematology Market 68
3.1.7.4 Australia Clinical Hematology Market 69
3.1.8 Remaining World Clinical Hematology Market 69
3.1.9 Overview of Asian Healthcare Market 70
3.1.9.1 Singapore 70
3.1.9.2 Malaysia 70
3.1.9.3 Thailand 70
3.1.9.4 Indonesia 71
3.1.9.5 Philippines 71
3.1.9.6 South Korea 72
3.1.9.7 Hong Kong 72
3.1.9.8 Taiwan 72
3.1.10 Overview of the Latin American Diagnostics Market 73
3.2 Clinical Hematology Analyzer and Reagents Sector 73
3.2.1 Industry-Served Markets 73
3.2.2 Industry Players 75
3.2.2.1 Manufacturing Companies 75
3.2.3 Market Specialization 75
3.2.4 Hematology Sector Companies 76
3.3 Outlook for Clinical Hematology Analyzer Testing 77
3.3.1 Long-Term Changes 77
3.3.2 Market Drivers 78
3.3.3 The Limits to Growth 79
3.3.4 Hot Sectors in the IVD Market 79
3.3.5 Key Technologies 79
3.3.6 Conclusion 80

4. Clinical Hematology Instrument Market by Type and Competitor 81
4.1 Abbott Diagnostics 81
4.2 Bayer Diagnostics 84
4.3 Beckman Coulter 85
4.4 Drew Scientific 87
4.5 Horiba ABX Inc. 88
4.6 Sysmex 89
4.7 Boule Medical 94
4.8 Beijing Shining Sun 95
4.9 Hematology Analyzers for Point of Care 95

For more information, please visit :
http://www.aarkstore.com/reports/Hematology-Analyzer-Instrumentation-and-Reagent-Markets-1314.html
Or email us at [email protected] or call +919272852585

Global Weight Management Market – Unraveling the opportunities

“Global Weight Management Market Report” aims to identify and analyze products and services that specifically induce weight loss and enable individuals to maintain weight. The global weight management market is estimated to reach US$586 billion in 2014 from about US$363 billion in 2009.

Device and accessories is the largest market under weight management, and is expected to be US$181 billion in size by 2014, owing to the role of brands targeting the youth, and growing adoption rate in the female population. However, the highest CAGR of 14.7% from 2009 to 2014 is expected to come from the services segment. Artificial sweeteners used in low calorie food and beverages such as hoodia gordonii, inulin etc are driving the CAGR of ingredients in low calorie F&B to about 11.2% from 2009 to 2014. Emergence of new artificial sweeteners that claim to preserve the traditional flavors are gaining in demand.

Weight management service market is lucrative as it exhibits the highest CAGR over the period of 2009 to 2014. There are not many food chains which specialize in serving health food. Diet chains service providers are now expanding this low tapped segment by providing better and healthy food.

The market is currently restrained due to a confused positioning. Number of weight loss methods available in the market are making it difficult for market players to drive brand recall among the consumers. Failed attempts to reduce weight by the consumers discourage them to go in for further weight loss trials. Hence it is very essential for market players to understand the target audience and their specific needs to provide them umbrella solutions.

The significantly high rate of new products in the weight management segment necessitates industry participants to adopt proactive strategies. Moreover, the larger chunk of the market is not only driven by significant products such as fitness devices and food market, there also exist added opportunities in the minor market such as for fitness accessories. This necessitates a further need to understand clearly the characteristics and demand for the micro-markets so as to obtain a holistic view of the industry. North America is the largest market for weight management. However, Europe is catching up with an expected CAGR of 10.2% during the period 2009 to 2014, owing to increased adoption of the services and products. Asian markets are expected to ensure long term growth due to increased health awareness.

The weight management market is highly fragmented and dominated by the unorganized sector. The key players in the weight management market are Abbott Nutrition, GSK, Roche, Atkins Nutritionals, Brunswick, Jenny Craig, Kellogg, Merck, McNeil Nutritionals, Nestle, Reebok and Unilever. Agreements and collaborations, and new product launches are very popular strategies to combat competition. Both these strategies are consequential as several of the market players are entering into agreements and collaborations in order to promote their new products and to extend their presence in new geographies with no or very less cost compared to acquisitions. Our patent analysis indicates that rise in the obesity concerns has resulted in an apparent increase in the number of patents especially for weight loss ingredients and diet food products in 2008.

What makes our reports unique?

1. We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 5.

2. Each report is about 250 pages with 100+ market data tables, 40 competitive company profiles, analysis of 300 patents and minimum 50 micro markets, which are collectively exhaustive and mutually exclusive.

3. No single report by any other publisher provides market data for all the segments viz products, services, applications, ingredients, technology, and stakeholders in a single report for all the four geographies – US, Europe, APAC, ROW.

4. We provide 10% customization- normally it is seen that clients do not find specific market intelligence that they are looking for. Our customization Our customization will ensure that you necessarily get the market intelligence you are looking for and we get a loyal customer.

5. 15 pages of high level analysis including benchmarking strategies, best practices and the market?s cash cows (BCG matrix). We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.

6. Comprehensive market analysis for pharmaceutical and biotech companies, medical device manufacturers, pharma-research labs, doctors, physicians and hospitals, medical/pharma associations, retailers and super-retailers, technology providers, and research and development (R&D) companies.

Key questions answered

1. Which are the high-growth segments/cash cows and how is the market segmented in terms of applications, products, services, ingredients, technologies, stakeholders?

2. What are market estimates and forecasts; which markets are doing well and which are not?

3. Where are the gaps and opportunities; what is driving the market?

4. Which are the key playing fields? Which are the winning edge imperatives?

5. How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

Powerful Research and analysis

The analysts working come from renowned publishers and market research firms globally adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We are inspired to help our clients grow by providing qualitative business insights with our huge market intelligence repository.

For more information, please visit :
http://www.aarkstore.com/reports/Global-Weight-Loss-and-Diet-Management-2009-2014–16958.html
Or email us at [email protected] or call +919272852585

Drug Device Combination – a High Growth Market

Drug-device combination is defined as the combination of drugs and medical devices that can be chemically or physically united or co-packaged as separate, cross labeled products. The commercialization cycle from R&D to product shows the immense potential of the bundled offering. Currently, the market has a potential of US$10.6 billion and has been experiencing a growth of 15% CAGR for the past two years. In the next five years, the market is expected to grow at a CAGR of 11.8%. A future view of the drug-device combination is that these products will make single component medical devices obsolete.

The drug-eluting stents (DES) market is the largest segment in the drug-device combination market. This is supported by the fact that cardiovascular applications constitute about 64% of the entire drug-device combination applications market. However, it is the relatively smaller market of antimicrobial catheter that offers the highest growth potential over the next five years in the overall market.

The DES market is further segmented into stent grafts, coronary stents and peripheral vascular stents. Though coronary stents has the highest market share, peripheral vascular stents is expected to have the highest growth rate till 2014. The fastest growing macro-market of antimicrobial catheter is segmented into micro-markets such as urological catheter, cardiovascular catheter, peripherally inserted central catheter, oximetry catheter, thermodilution catheter and wound drainage catheter. Closed loop glucose monitor and insulin pump is also expected to record a high growth rate for the period 2009 to 2014. The two major segments: steroid eluting electrodes and photodynamic therapy are estimated to see the slowest growth rate due to a slow development of new products in these markets.

The challenges crippling the growth of the market in the future are expected to be the issues involved in cross industry partnerships, jurisdiction issues, patient safety and interoperability issues.

The drug-device combination market is not fragmented and the key players in this market are Medtronic, Boston Scientific Corp., Edwards Life sciences Corp., Stryker Corp., QLT Inc. etc. The maximum number of new product developments is expected to take place in the bone graft substitutes, advanced wound care products and antimicrobial catheter markets. Our patent analysis indicates that E.U. has filed for the maximum number of patents followed by the U.S.

There is an immense scope of collaboration between the drugs and medical devices companies in the areas of closed loop glucose monitor and insulin pump, bone graft substitutes and advanced wound care products market. However, the antibiotic bone cements and advanced wound care market is expected to face stiff competition in the next five years to come.

The incremental benefits of these combination products over the regular medical devices are increased efficiency, reduction in overall cost of treatment along with the rising awareness. The market holds significant opportunity for the early movers albeit with extensive research to develop new and improved products at competitive prices. Successful strategic alliances between companies from the drugs and medical devices areas assist them in taking advantage of the existing technologies by avoiding capital expenditure in R&D and take the drug-device combination market to new heights.

What makes our reports unique?

1. We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 5.

2. Each report is about 250 pages with 100+ market data tables, 40 competitive company profiles, analysis of 300 patents and minimum 50 micro markets, which are collectively exhaustive and mutually exclusive.

3. No single report by any other publisher provides market data for all the segments viz products, services, applications, ingredients, technology, and stakeholders in a single report for all the four geographies – US, Europe, APAC, ROW.

4. We provide 10% customization- normally it is seen that clients do not find specific market intelligence that they are looking for. Our customization Our customization will ensure that you necessarily get the market intelligence you are looking for and we get a loyal customer.

5. 15 pages of high level analysis including benchmarking strategies, best practices and the market?s cash cows (BCG matrix). We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.

6. Comprehensive market analysis for pharmaceutical and biotech companies, medical device manufacturers, pharma-research labs, doctors, physicians and hospitals, medical/pharma associations, retailers and super-retailers, technology providers, and research and development (R&D) companies.

Key questions answered

1. Which are the high-growth segments/cash cows and how is the market segmented in terms of applications, products, services, ingredients, technologies, stakeholders?

2. What are market estimates and forecasts; which markets are doing well and which are not?

3. Where are the gaps and opportunities; what is driving the market?

4. Which are the key playing fields? Which are the winning edge imperatives?

5. How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

Powerful Research and analysis

The analysts working with MarketsandMarkets come from renowned publishers and market research firms globally adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We, at MarketsandMarkets, are inspired to help our clients grow by providing qualitative business insights with our huge market intelligence repository.

For more information, please visit :
http://www.aarkstore.com/reports/Drug-and-Device-Combination-2009-2014–16959.html
Or email us at [email protected] or call +919272852585